Skip to main content
. 2015 Dec 10;114(2):163–170. doi: 10.1038/bjc.2015.419

Figure 2.

Figure 2

Efficacy according to the development of HFS in patients receiving bevacizumab plus capecitabine treatment. (A) PFS; (B) OS. CI=confidence interval; HFS=hand-foot syndrome; OS=overall survival; PFS= progression-free survival.